Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-11-16. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 42.9% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellleukemiastagechemotherapyacute
  Phrases that lowered it: hepatitischaracteristics ofand safetypositiveperiod
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 17.6% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 29841 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 129331 (lowers risk) · Drug's FDA history
• Maximum age: 17 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 22 (lowers risk) · Sponsor's track record
• Disease area, infectious disease: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Drugs with FDA adverse-event history: 6 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 78.6% (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Minimum age: 0.5 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation NCT01516567 · started 2012 · scored riskier than 59% of active trials completed
• Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma NCT00987493 · started 2009 · scored riskier than 94% of active trials completed
• A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma NCT01796171 · started 2012 · scored riskier than 78% of active trials completed
• NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma NCT01451515 · started 2012 · scored riskier than 84% of active trials completed
• Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma NCT00599170 · started 2008 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.